• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 16, 2012

View Archived Issues

Genmab, J&J in $175M Per Product DuoBody Deal

Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets. It is banking $3.5 million up front and could receive up to $175 million more in milestone and license payments for each successfully developed product. Read More

Inhibiting Housekeeping Enzyme Wakes P53, in Cancer Cells Only

Researchers from the Australian Peter MacCallum Cancer Centre and colleagues, including some from Cylene Pharmaceuticals Inc., have reported that by inhibiting RNA Polymerase I with their preclinical compound CX-5461, they were able to activate p53 specifically in cancer cells – a feat that researchers have been trying to achieve "for many years," Cylene CEO William Rice told BioWorld Today. Read More

Cell Therapy Still Progressing Despite Many Challenges

DUBLIN – Small molecules may be hard enough to get through development and registration, but that is nothing like the challenge the industry is facing in attempts to get cell therapies to market. Read More

RedX Pharma Raising $17M for Antiviral, Antibody Work

LONDON – RedX Pharma Ltd. is planning a £10.8 million (US$16.8 million) investment to extend the reach of its expertise in the structural modification of marketed drugs into antibiotics and antivirals. Read More

IPO Problem Keeps Tick, Tick, Ticking for Small Firms

NEW YORK – Regulators are endeavoring to take steps to boost the prospects for small companies to partake in the initial public offering (IPO) market, but more can be done to help not only companies going public today, but those that went public in the pre-healthcare reform era and that have been burdened and are struggling with the side effects of overregulation for years, according to someone the SEC actually listens to. Read More

Stock Movers

Read More

Pharma: Other News To Note

• Watson Pharmaceuticals Inc., of Parsippany, N.J., said the FDA approved its abbreviated new drug application for Next Choice One Dose (levonorgestrel tablet, 1.5 mg), the generic equivalent to Jerusalem-based Teva Pharmaceutical Industries Ltd.'s Plan B One-Step. Watson plans to launch immediately. Read More

Other News To Note

• Ember Therapeutics Inc., of Boston, said a study published in Cell found that beige fat cells, which burn caloric energy like brown fat cells, are specifically targeted by the hormone irisin. The isolated beige fat cells are a type of brown fat cell that is distinct from the classic brown fat and are produced from white fat depots when triggered by specific conditions such as exercise and cold. Ember recently completed a licensing agreement with the Dana-Farber Cancer Institute for intellectual property related to that beige fat discovery. Read More

U.S. Patent Disclosures

• Organovo Holdings Inc., of San Diego, received U.S. Patent No. 8,143,055, titled "Self-assembling multicellular bodies and methods of producing a three-dimensional biological structure using the same," which covers one of its core bioprinting technologies. Read More

Bench Press - BioWorld Looks at Translational Medicine

By looking at extreme phenotypes, researchers at the University of Washington have managed to identify a genetic contributor to cystic fibrosis patients' susceptibility to lung infections. Exome sequencing of families has been used to identify several genetic causes of rare monogenic diseases. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe